The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ACADEMIA
ACADEMIA
- Gunma Univ. Hospital Plans Clinical Research Covering Hydroxychloroquine
April 13, 2020
- BCG’s Efficacy in COVID-19 Not Yet Confirmed: Japan Vaccine Society
April 6, 2020
- Researchers Unlock SAL Inhibitory Mechanism of Obesity Med Orlistat; Potential Treatment for MRSA/Atopic Dermatitis
March 30, 2020
- Otsuka, NCC Develop Comprehensive Genomic Profiling Assay for Blood Cancer
March 27, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
- Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
- COVID-19 Patients in Japan Improved on Plaquenil
March 11, 2020
- Camostat Potential Treatment for COVID-19: German Study
March 11, 2020
- Alvesco Inhibits RNA Replications: NIID
March 9, 2020
- With Sudden Spotlight on Alvesco for COVID-19, Teijin Being Flooded with Inquiries
March 6, 2020
- Asthma Drug Alvesco Possibly Effective for COVID-19
March 4, 2020
- Kyoto Univ., NTT Launch New Company to Analyze, Provide RWD; Label Expansions Eyed for Cancer Drugs
February 5, 2020
- TMDU Research Team Calls for New Hypothesis on Cause of AD; Could Lead to Development of Gene Therapy
January 28, 2020
- Impact of Oligonucleotides - 3: Advances in Modified Oligo Technologies Pave Way for Innovative Drug Arrivals
January 20, 2020
- Nagasaki Univ., Kobe Foundation Tie Up on Clinical Development
January 17, 2020
- Impact of Oligonucleotides - 2: Expert Says Spinraza Changed SMA Treatment Paradigm, Has High Expectation for Zolgensma Too
January 17, 2020
- Impact of Oligonucleotides - 1: Onpattro a Major Advance in FAP Treatment, but Challenges Remain
January 16, 2020
- Leading IBD Care Hospital Switches to Infliximab Biosimilars; Will Others Follow Suit?
January 7, 2020
- 5-Year Cancer Survival Rate Rises 0.3 Point to 66.4%: NCC
December 17, 2019
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…